SUPN

Business Context and Reporting Period

Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: July 23, 2024
Context: This filing announces the scheduled release of financial results for the second quarter of 2024. The company plans to report results after market close on August 6, 2024, followed by a conference call and webcast at 4:30 p.m. E.T.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a notice of the upcoming earnings announcement and does not contain the actual financial data for the period.

Material Changes

No material changes to financial performance or operations are detailed in this filing. The document contains no comparative data versus prior periods.

Guidance, Outlook, and Management Commentary

Upcoming Events:

• Earnings Release Date: August 6, 2024 (after market close).
• Conference Call: August 6, 2024 at 4:30 p.m. E.T.

Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) regarding the announcement but does not include specific management commentary, guidance, risks, or contingencies within the body of this 8-K text.

Investor Verification Checklist

• Verify the actual Q2 2024 financial results when released on August 6, 2024.
• Review the full text of the press release filed as Exhibit 99.1 for any preliminary guidance or specific operational updates.
• Listen to the conference call on August 6, 2024, for management's discussion of financial condition and outlook.
• Confirm the trading symbol (SUPN) and exchange (Nasdaq) for accurate market data tracking.